Pioglitazone Decreases Hepatitis C Viral Load in Overweight, Treatment Naïve, Genotype 4 Infected-Patients: A Pilot Study

• Mario Chojkier ,

  * E-mail: mchojkier@ucsd.edu

  Affiliations Department of Medicine, San Diego VA Healthcare System, San Diego, California, United States of America, Department of Medicine, University of California San Diego, La Jolla, California, United States, Biomedical Sciences Program, University of California San Diego, La Jolla, California, United States of America, Clinical Translational Research Institute, University of California San Diego, La Jolla, California, United States of America

  ⨯
• Hisham Elkhayat,

  Affiliations Hepatology Department, Theodor Bilharz Research Institute, Giza, Egypt, Hepatology Clinic, Agouza Hospital, Ministry of Health, Giza, Egypt

  ⨯
• Dina Sabry,

  Affiliation Department of Medical Biochemistry, Faculty of Medicine, Cairo University, Cairo, Egypt

  ⨯
• Michael Donohue,

  Affiliations Clinical Translational Research Institute, University of California San Diego, La Jolla, California, United States of America, Division of Biostatistics and Bioinformatics, Department of Family and Preventive, University of California San Diego, San Diego, California, United States of America

  ⨯
• Martina Buck

  Affiliations Department of Medicine, San Diego VA Healthcare System, San Diego, California, United States of America, Department of Medicine, University of California San Diego, La Jolla, California, United States, Biomedical Sciences Program, University of California San Diego, La Jolla, California, United States of America

  ⨯